[
    [
        {
            "time": "2018-03-15",
            "original_text": "Teva's Trisenox Gets FDA Approval as First-Line Treatment",
            "features": {
                "keywords": [
                    "Teva",
                    "Trisenox",
                    "FDA Approval",
                    "First-Line Treatment"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Teva's Trisenox Gets FDA Approval as First-Line Treatment",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Risks",
                    "Underappreciated",
                    "Goldman Sachs",
                    "Downgrade"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "The Race To Find A Treatment For NASH",
            "features": {
                "keywords": [
                    "Race",
                    "Treatment",
                    "NASH"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The Race To Find A Treatment For NASH",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]